TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
Jiang B, Hu L, Dong D, Guo Z, Wei W, Wang C, Shao W, Ma T, Chen Y, Li Q, et al. J Cancer Res Clin Oncol. 2023 Sep; 149(12):10041-10052. Epub 2023 Jun 1.